Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label combination therapy trial in chronic hepatitis B
2021-005132-33Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tomligisiran and nivolumab in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Primary endpoint: HBsAg seroclearance at follow-up Week 24. Started Feb 2022; status: completed.
02
Drugs
tomligisirannivolumab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2021-005132-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005132-33.